Complementary prediction of cardiovascular events by estimated apo- and lipoprotein concentrations in the working age population. The Health 2000 Study

References

• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Warnick GR, Myers GL, Cooper GR, Rifai N. Impact of the third cholesterol report from the adult treatment panel of the national cholesterol education program on the clinical laboratory. Clin Chem. 2002;48:11–17.
   PubMed Web of Science ®Google Scholar
• Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem. 2009;55:888–94.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Dunn M, Liu C, Liu C, Selzer RH, . Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 1997;95:2022–6.
   PubMed Web of Science ®Google Scholar
• Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762–70.
   Google Scholar
• Majeed F, Miller M. Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment. Curr Opin Endocrinol Diabetes Obes. 2008;15:175–81.
   Google Scholar
• Bruckert E, Hansel B. HDL-c is a powerful lipid predictor of cardiovascular diseases. Int J Clin Pract. 2007;61:1905–13.
   Google Scholar
• Morgan J, Carey C, Lincoff A, Capuzzi D. High-density lipoprotein subfractions and risk of coronary artery disease. Curr Atheroscler Rep. 2004;6:359–65.
   PubMedGoogle Scholar
• Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, . Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation. 1996;94:273–8.
   PubMed Web of Science ®Google Scholar
• Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, . Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation. 2000;101:477–84.
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026–33.
   PubMed Web of Science ®Google Scholar
• McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, . Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372:224–33.
   PubMed Web of Science ®Google Scholar
• Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, . Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol. 2007;50:1735–41.
   PubMed Web of Science ®Google Scholar
• Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112: 3375–83.
   PubMed Web of Science ®Google Scholar
• St-Pierre AC, Cantin B, Dagenais GR, Mauriège P, Bernard PM, Després JP, . Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25:553–9.
   PubMed Web of Science ®Google Scholar
• Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211–28.
   PubMed Web of Science ®Google Scholar
• Brufau G, Groen AK, Kuipers F. Reverse cholesterol transport revisited: contribution of biliary versus intestinal cholesterol excretion. Arterioscler Thromb Vasc Biol. 2011;31:1726–33.
   Google Scholar
• Tremblay AJ, Morrissette H, Gagne JM, Bergeron J, Gagne C, Couture P. Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population. Clin Biochem. 2004;37:785–90.
   PubMed Web of Science ®Google Scholar
• Niemi J, Makinen VP, Heikkonen J, Tenkanen L, Hiltunen Y, Hannuksela ML, . Estimation of VLDL, IDL, LDL, HDL(2), apoA-I, and apoB from the Friedewald inputs—apoB and IDL, but not LDL, are associated with mortality in type 1 diabetes. Ann Med. 2009;41:451–61.
   PubMed Web of Science ®Google Scholar
• Kattainen A, Salomaa V, Harkanen T, Jula A, Kaaja R, Kesäniemi YA, . Coronary heart disease: from a disease of middle-aged men in the late 1970s to a disease of elderly women in the 2000s. Eur Heart J. 2006;27:296–301.
   PubMed Web of Science ®Google Scholar
• Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Räihä P, Kärjä-Koskenkari P, . The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2005;12:132–7.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11–21.
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D’Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med. 2010;48:1703–11.
   PubMed Web of Science ®Google Scholar
• Kundu S, Aulchenko YS, van Duijn CM, Janssens AC. PredictABEL: an R package for the assessment of risk prediction models. Eur J Epidemiol. 2011;26:261–4.
   PubMed Web of Science ®Google Scholar
• Harrell, F. E. ImproveProb() routine in Hmisc package, R package version 3.9-0. Nashville, Tennessee Vanderbilt University Department of Biostatistics. URL: http://biostat.mc.vanderbilt.edu/s/Hmisc.
   Google Scholar
• D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–53.
   PubMed Web of Science ®Google Scholar
• Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006;26: 847–70.
   PubMed Web of Science ®Google Scholar
• Teng B, Thompson GR, Sniderman AD, Forte TM, Krauss RM, Kwiterovich PO Jr. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia. Proc Natl Acad Sci USA. 1983;80: 6662–6.
   PubMed Web of Science ®Google Scholar
• Otvos J. Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. Clin Cardiol. 1999;22(6 Suppl): II21–7.
   Google Scholar
• Pradhan A. Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev. 2007;65(Pt 2): S152–6.
   Google Scholar
• ; Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors CollaborationSarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, . Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634–9.
   PubMed Web of Science ®Google Scholar
• Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011;13:544–52.
   PubMedGoogle Scholar
• Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol. 2010;55:1283–99.
   PubMed Web of Science ®Google Scholar
• Kontush A, Chapman MJ. Antiatherogenic small, dense HDL—guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med. 2006;3: 144–53.
   PubMedGoogle Scholar
• Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J. 2005;26:271–8.
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence. J Intern Med. 2006;259:493–519.
   PubMed Web of Science ®Google Scholar
• Juonala M, Viikari JS, Kahonen M, Solakivi T, Helenius H, Jula A, . Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study. J Am Coll Cardiol. 2008;52:293–9.
   PubMed Web of Science ®Google Scholar
• Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohrvik J, . Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J. 2009;30:710–7.
   PubMed Web of Science ®Google Scholar
• Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med. 2006;259:481–92.
   PubMed Web of Science ®Google Scholar
• Luc G, Bard JM, Ferrieres J, Evans A, Amouyel P, Arveiler D, . Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Arterioscler Thromb Vasc Biol. 2002;22:1155–61.
   PubMedGoogle Scholar
• Silva RA, Huang R, Morris J, Fang J, Gracheva EO, Ren G, . Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc Natl Acad Sci U S A. 2008;105:12176–81.
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, . Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31:811–22.
   PubMed Web of Science ®Google Scholar
• Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, . 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can J Cardiol. 2009;25:567–79.
   PubMed Web of Science ®Google Scholar